Non-type 1 and non-type 2 diabetes in a young man due to novel mutation in HNF1A Authors: Yi-Chen Liu, Sheng-Chiang Su, Feng-Chih Kuo, Yi-Jen Hung, Yen-Lin Chen Published: 2025 ABSTRACT SummaryMaturity-onset diabetes of the young (MODY) is an autosomal dominant monogenic form of diabetes. This report describes a case with hepatocyte nuclear factor 1-alpha (HNF1A)-MODY due to a novel heterozygous HNF1A mutation. The patient presented with hyperglycaemia and glycosuria in the absence of diabetic ketoacidosis. Family history was notable for early-onset diabetes. Genetic testing confirmed a previously unreported pathogenic HNF1A variant. Treatment with a GLP-1 receptor agonist and metformin reduced glycated haemoglobin from 10.2% to 6.0% within 3 months. This case highlights the importance of genetic screening in early-onset diabetes, which is frequently misdiagnosed as type 1 or type 2 diabetes, and expands the spectrum of HNF1A mutations relevant to precision medicine.Keywords: Diabetes, Genetics, Genetic screening / counselling Background Maturity-onset diabetes of the young (MODY) is defined as a group of dominantly inherited, non-autoimmune diabetes disorders characterised by a primary defect in the development and function of pancreatic β-cells. These conditions typically manifest and are diagnosed before the age of 25.1 Approximately 1%–6% of young-onset diabetes cases are due to MODY.2 In various ethnic and racial groups, MODY may exhibit different prevalence rates, which could potentially be underestimated. To date, research has mainly concentrated on White European populations.3 Recent studies have investigated the prevalence of MODY in Asian and Australian regions.4 5 Estimates of the prevalence of MODY vary significantly. This variation often occurs because genetic screening is typically limited to individuals based on clinical characteristics, even within studies involving populations.5 Relevant mutations in over 15 genes have been linked to the MODY-monogenic phenotype, each corresponding to different therapeutic strategies.2 The majority of observed cases in various MODY types are primarily due to mutations in genes such as hepatocyte nuclear factor 1-alpha (HNF1A), glucokinase, hepatocyte nuclear factor 4-alpha and hepatocyte nuclear factor 1-β.6 7 HNF1A-MODY represents the predominant type of MODY, constituting about 30%–65% of all MODY cases, with a clearly observable autosomal dominant transmission of symptomatic diabetes in families.8 In early adolescence, symptoms may not be apparent, and elevated blood glucose levels are frequently identified unexpectedly during routine blood testing, typically without any clinical indications of insulin resistance. Checking blood sugar levels after meals or conducting a 2-hour oral glucose tolerance test (OGTT) can identify a significant increase in postprandial glucose (≥11.1 mmol/L). Additionally, glycosuria might be detected, which is attributed to a reduced renal threshold for glucose reabsorption resulting from compromised glucose transport in renal tubules.9 However, in the later stages of the disease, symptoms such as polydipsia, polyuria, polyphagia and body weight loss, similar to those observed in type 1 and type 2 diabetes (T2D), can be seen. Therefore, differentiating MODY from type 1 and T2D remains a diagnostic dilemma due to overlapping clinical features.8 Currently, several diagnostic algorithms for MODY have been established in studies.2 10 After a physical examination and family history assessment suggest a clinical presentation of MODY and with the presence of negative autoantibodies associated with type 1 diabetes, including glutamic acid decarboxylase antibodies (GADA), insulinoma antigen-2 autoantibody (IA-2A) and zinc transporter 8 (ZnT8), along with other supporting biochemical tests, molecular genetic testing holds a significant role in diagnosis. A precise diagnosis is crucial for determining the right treatment approach, forecasting potential complications, assessing prognosis and facilitating family counselling. Contemporary studies have discovered that hundreds of different mutations in the HNF1A gene are responsible for HNF1A-MODY.11 In the case reported in the present paper, we identified a novel heterozygous substitution, p.N270S (HNF1A:c.809A>G), in exon 4 of HNF1A in a HNF1A-MODY patient by genetic testing using NGS (next-generation sequencing) panel and analysed for pathogenicity according to American College of Medical Genetics (ACMG) guidelines for variant interpretation. This mutation was not reported in the literature, VarSome database nor ClinVar database. Written informed consent was obtained directly from the patient for publication of this case report. Case presentation A young adult was referred for evaluation of hyperglycaemia and glycosuria during his annual health examination. On examination, his BMI was 24.6 kg/m2, blood pressure was 112/70 mmHg and heart rate was 78 beats per minute. Acanthosis nigricans was not observed during the physical examination. Family history was notable for early-onset diabetes, with the maternal grandmother diagnosed in her 30s, the mother in her late 20s and the younger brother at age 20. There was no known history of early-onset cardiovascular disease among family members diagnosed with diabetes. Investigations His glycated haemoglobin (HbA1c) was 10.2% (88 mmol/mol), and his fasting glucose was 12.4 mmol/L. A 2-hour glucose level post 75 g OGTT was 19.8 mmol/L. There were no signs of diabetic ketoacidosis. The patient reported increased thirst, increased appetite and recent weight loss. The lipid profile revealed an high-density lipoprotein level of 1.01 mmol/L and triglycerides of 4.31 mmol/L, suggesting a possible metabolic syndrome (see tables1 2). The patient had no significant medical or surgical history. Table 1Results of clinical chemistry testsLaboratory (serum)Tests resultReference rangeTSH (mIU/L)2.420.25–5.0HDL-C (mmol/L)1.01>1.03LDL-C (mmol/L)2.56<2.6Triglyceride (mmol/L)4.30<2.26Total cholesterol (mmol/L)4.90<5.2Creatinine (μmol/L)88.462–106ALT (IU/L)14<41Uric acid (μmol/L)327137–420HbA1c (%)10.24.0–6.0ALT, alanine aminotransferase; HbA1c, glycated haemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TSH, thyroid-stimulating hormone. Results of clinical chemistry tests ALT, alanine aminotransferase; HbA1c, glycated haemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TSH, thyroid-stimulating hormone. Table 22-hour OGTT (oral glucose tolerance test)Laboratory (serum)Tests resultReference rangeGlucose 0′ (mmol/L)12.43.9–5.5Glucose 120′ (mmol/L)19.8<7.8 2-hour OGTT (oral glucose tolerance test) Glucagon stimulation test showed a serum C-peptide level of 0.39 nmol/L at 0 min and 0.83 nmol/L at 6 min, indicating insufficient insulin secretion. This test evaluates residual β-cell function by measuring stimulated C-peptide levels after glucagon injection. In clinical practice, a stimulated C-peptide level>0.60 nmol/L generally indicates preserved endogenous insulin secretion, whereas lower levels suggest β-cell dysfunction.12 However, the glucagon stimulation test should be regarded as supportive rather than definitive, particularly in cases where autoantibody results are inconclusive or the clinical presentation is atypical. Microalbuminuria was not detected. Sudomotor testing demonstrated severely reduced sudomotor function over the hands. Sudomotor function was assessed using electrochemical skin conductance testing (eg, via Sudoscan), a non-invasive tool that evaluates small fibre autonomic nerve activity. The patient’s results demonstrated severely reduced conductance in the hands, indicating significant autonomic dysfunction. Both antibody tests, including GADA and islet antigen 2 antibodies (IA-2A), were negative. One month postdiagnosis, a MODY genetic test was performed, revealing a heterozygous, pathogenic (P) variant in HNF1A (p.N270S (HNF1A:c.809A>G)), consistent with HNF1A-MODY. Treatment At the time of diagnosis, the patient presented with significantly elevated HbA1c and plasma glucose levels. The initial treatment regimen consisted of a basal insulin degludec (eight units/day), in combination with metformin (1500 mg/day) and saxagliptin (5 mg/day), reflecting a preliminary consideration of T2D. This strategy aimed to achieve rapid glycaemic control while addressing potential insulin resistance. In addition to pharmacological therapy, the patient was advised to adhere to a structured dietary plan and engage in regular physical activity as part of a comprehensive diabetes management approach. Follow-up evaluations were conducted at the endocrinology and metabolism outpatient clinic to monitor glycaemic control and assess treatment response. However, given the patient’s moderately preserved yet insufficient β-cell function on glucagon stimulation test (stimulated C-peptide: 0.83 nmol/L), negative islet autoantibodies and a strong family history of early-onset diabetes, there was a high clinical suspicion of MODY. Initial treatment was started prior to the availability of genetic testing results, based on the clinical presentation and laboratory findings at diagnosis. Outcome and follow-up One month later, the patient’s HbA1c decreased to 9.1%. Following genetic confirmation of HNF1A-MODY and considering the patient’s moderately preserved yet insufficient β-cell function, along with an improvement in HbA1c to 9.1%, insulin therapy was discontinued and replaced with dulaglutide (GLP-1 receptor agonist, 1.5 mg weekly) to support glycaemic control and preserve pancreatic function. After 6 months of treatment, the patient’s HbA1c decreased to 6.0%, indicating significant improvement. As glycaemic control stabilised, the regimen was subsequently simplified to a combination of metformin (1500 mg/day) and the DPP-4 inhibitor saxagliptin (5 mg/day) for long-term maintenance therapy. The patient remains under regular follow-up, with HbA1c consistently maintained below 6.5%. To date, there have been no signs of microalbuminuria or diabetic retinopathy, and ongoing surveillance for long-term complications is being conducted. Discussion The HNF1A gene is a transcription factor located in the q24 region of chromosome 12. It comprises 10 exons spanning 23 790 base pairs and encodes a protein of 631 amino acids, which is expressed in various tissues, including the liver, kidneys and pancreas.1 Mutations in HNF1A lead to a progressive decline in β-cell function, manifested by impaired expression of insulin and GLUT2 genes, as well as reduced pyruvate kinase activity. Ultimately, this results in decreased insulin secretion and glucose intolerance.13 The diagnostic process in this case adhered to the current MODY diagnostic criteria, which encompass clinical, biochemical and genetic evidence, including early onset of diabetes, strong family history, postprandial blood glucose intolerance and negative autoantibodies. Preserved fasting C-peptide level greater than 0.6 ng/mL suggests a diagnosis of non-type 1 diabetes.2 14 However, subsequent monitoring of C-peptide levels is essential because normal values may be observed in the early stages of type 1 diabetes. A significant barrier to the diagnosis of MODY is the lack of awareness and clinical suspicion. These patients are often misdiagnosed as having type 1 or T2D. The MODY probability calculator developed by the Exeter group can aid clinicians in identifying candidates for genetic testing. However, this tool was derived from data in a White European population and may overestimate the probability of MODY in non-White groups. When the clinical information of our patient was entered into this calculator, the estimated probability of having MODY was 62.4% (a 1 in 1.6 chance).15 Several case reports have described the presence of autoantibodies in patients with MODY. Some individuals with HNF1A mutations have autoantibodies, although the majority of MODY cases are autoantibody negative.16 Earlier studies show that obesity and metabolic syndrome rates are lower in MODY patients than in those with T2D. However, as obesity rates rise, distinguishing between MODY and T2DM using BMI or metabolic syndrome has become less effective, which may explain the higher BMI in our case. Additionally, while family history is an important factor for MODY, its usefulness may be limited due to under-reporting, new mutations and the high prevalence of T2DM family history.4 The treatment for HNF1A-MODY is determined by age and HbA1c levels. First-line therapy involves low-dose sulfonylureas, which enhance insulin secretion by acting on potassium-sensitive ATP channels.2 In patients with HNF1A-MODY, GLP-1 receptor agonists can serve as a safer and more effective alternative to sulfonylureas as β-cell function declines, particularly in individuals prone to hypoglycaemia. A small, randomised, double-blind, crossover trial demonstrated that both liraglutide and glimepiride effectively reduce fasting plasma glucose and postprandial glucose fluctuations, with no significant differences between the two treatments in patients with HNF1A-MODY. Additionally, GLP-1 receptor agonist therapy presents a lower risk of mild hypoglycaemia compared with glimepiride.13 14 17 Through genetic diagnosis, we were able to discontinue insulin after achieving glycaemic control and transition the patient to GLP-1 receptor agonist therapy, which maintained effective glucose management. This highlights the critical value of genetic testing in guiding treatment decisions. Glycosuria in HNF1A-MODY is attributed to reduced expression of SGLT2, which is under the transcriptional control of HNF1A. A report indicated that HNF1A-MODY patients may experience severe dehydration and diabetic ketoacidosis due to high inhibition of residual SGLT-2 activity. The risks associated with using SGLT-2 inhibitors in HNF1A-MODY patients, such as increased dehydration risk, potential vascular collapse, genital infections and diabetic ketoacidosis, may outweigh the potential benefits of these medications.2 16 In this case, the treatment regimen of liraglutide and metformin is effective and safe, consistent with previous studies. Precision medicine is crucial for MODY, as patients with HNF1A-MODY often fail to meet all diagnostic criteria despite existing clinical guidelines. Currently, there are no suitable biomarkers to differentiate HNF1A-MODY from type 1 and T2D. A study by Chen et al indicated that among 2429 young Chinese adults with early-onset T2D, the prevalence of MODY was 1.5%, with 0.74% carrying P or likely pathogenic (LP) MODY variants.4 Research by Møller et al highlighted that in a large population-based sample of Danish Caucasian patients with type 1 diabetes, 10% of 39 patients who did not carry any high-risk HLA haplotypes were found to harbour mutations in the HNF1A gene.18 Similarly, a recent population-based study from Russia screened 506 individuals suspected of having hereditary forms of diabetes without autoimmune features—based on negative IAA, ICA, GADA and ZnT8 antibodies at onset, preserved C-peptide secretion, low insulin requirements within 5 years and absence of severe obesity. The study identified P or LP variants in 46.4% of these patients, with HNF1A among the most commonly affected genes.19 DNA sequencing is essential for confirming MODY clinical suspicions.20 NGS allows for the analysis of large amounts of patient DNA in a single reaction, improving the feasibility of MODY screening. With the development of NGS, many new genetic variants have been discovered. The ACMG provides guidelines to evaluate whether these variants are P.21 Over 1000 distinct HNF1A variants have been reported in databases such as ClinVar, including P, LP, benign, likely benign and variants of uncertain significance. In our case, the novel heterozygous HNF1A variant (c.809A>G, p.N270S) was absent from ClinVar and other commonly used variant databases, highlighting its novelty rather than questioning its clinical relevance. Importantly, this variant affects an amino acid residue adjacent to known P residues, exhibits a high AlphaMissense score (0.995) and segregates with diabetes in the family, all of which meet ACMG criteria for a LP’ classification. Thus, while ClinVar is a valuable resource for cataloguing reported variants, the pathogenicity of this variant is supported by multiple independent lines of genetic and clinical evidence beyond database records. Studies have indicated that the majority of identified mutations are located in the DNA-binding domain, while the transactivation domain has a lower mutation rate.22 23 The new variant reported in this case is situated in the DNA-binding domain. Some studies show that HNF1A mutations, while P, have minimal effects on HNF1A protein function. Additionally, some HNF1A variants unable to cause MODY alone may be associated with an increased risk of T2D.11 24 In conclusion, this case highlights the importance of accurate diagnosis of HNF1A-MODY and its impact on individual treatment. Further research will focus on developing more effective NGS screening strategies to improve the diagnostic rate of MODY, achieving better cost management and clinical benefits. Patient’s perspective I usually feel fine, except that I had been feeling thirstier and hungrier than usual recently. To apply for military school, I took the required medical examination, and that’s when I unexpectedly discovered that my blood sugar levels were significantly higher than normal. I then went to a medical centre for further testing, where the doctor diagnosed me with diabetes and mentioned that I might need insulin treatment. Hearing this made me quite nervous. On top of that, the doctor warned me that if I didn’t manage my blood sugar properly, I could develop complications affecting other organs in the future. That left me feeling even more lost. My mom also scolded me, saying that I never exercised and always ate junk food, which led to this diagnosis. Looking back, I did enjoy eating fried chicken and drinking bubble tea, but I wasn’t as overweight as my younger brother. The doctor advised me to be hospitalised for a more detailed examination and undergo genetic testing. Later, the doctor told me that I actually had monogenic diabetes, which was more related to family genetics. That news relieved a lot of my guilt. Most importantly, I now understand the importance of keeping my blood sugar under control and will continue to manage it carefully. Learning points Early-onset diabetes with strong family history, negative autoantibodies and preserved C-peptide secretion should prompt consideration of hepatocyte nuclear factor 1-alpha-maturity-onset diabetes of the young (HNF1A-MODY), as exemplified by this young patient whose insulin therapy was successfully discontinued following genetic confirmation. Early-onset diabetes with strong family history, negative autoantibodies and preserved C-peptide secretion should prompt consideration of hepatocyte nuclear factor 1-alpha-maturity-onset diabetes of the young (HNF1A-MODY), as exemplified by this young patient whose insulin therapy was successfully discontinued following genetic confirmation. Low-dose sulfonylureas serve as the first-line treatment for HNF1A-MODY. However, GLP-1 receptor agonists (GLP-1 RAs) may be an alternative option in cases of β-cell dysfunction, with a lower risk of hypoglycaemia. Low-dose sulfonylureas serve as the first-line treatment for HNF1A-MODY. However, GLP-1 receptor agonists (GLP-1 RAs) may be an alternative option in cases of β-cell dysfunction, with a lower risk of hypoglycaemia. Currently, no specific biomarker is available to differentiate HNF1A-MODY from type 1 or type 2 diabetes; therefore, genetic testing remains the gold standard for definitive diagnosis. Currently, no specific biomarker is available to differentiate HNF1A-MODY from type 1 or type 2 diabetes; therefore, genetic testing remains the gold standard for definitive diagnosis. Footnotes Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy. Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Consent obtained directly from patient(s). References